Transfer-pricing associated-enterprise rules require prescribed arm's-length methods, while enduring-benefit tests govern software and research expenditure.
Common shareholding of at least 26% voting power in each enterprise triggers associated-enterprise status under section 92A(2), supporting transfer-pricing scrutiny. Chapter X supplies a mechanism for computing the arm's-length value of international transactions; it does not create a separate charge of notional income, and section 92C requires a prescribed most appropriate method rather than ad hoc pricing. Capital scientific-research expenditure is deductible only when related to the taxpayer's own business, while unpaid leave encashment remains subject to the applicable payment condition. Software with an enduring benefit is capital, whereas one-year software may be revenue. Research expenditure intended to yield enduring benefit is capital even if research does not succeed.
Issues: (i) Whether common shareholding rendered the assessee and the overseas entities associated enterprises and validated the reference to the Transfer Pricing Officer; (ii) Whether Chapter X can bring to tax notional income absent an independent charge under sections 4 and 5; (iii) Whether an arm's-length-price adjustment made without selecting a prescribed most appropriate method could be sustained; (iv) Whether capital research expenditure qualified for deduction under section 35(1)(iv); (v) Whether an unpaid provision for leave encashment was deductible; (vi) Whether software expenditure was capital or revenue according to the duration of its benefit; (vii) Whether expenditure on a handy camera was allowable business or research expenditure rather than impermissible freebies; (viii) Whether research and development expenditure claimed as revenue expenditure under section 37 was capital expenditure.
Issue (i): Whether common shareholding rendered the assessee and the overseas entities associated enterprises and validated the reference to the Transfer Pricing Officer.
Analysis: Section 92A(2)(b) deems enterprises to be associated enterprises where a person holds not less than 26% voting power in each enterprise. The statutory deeming rule operates for the purposes of section 92A(1), and participation in management, control or capital is consequently presumed. The common shareholder held more than the prescribed threshold in the assessee and the parent company of the overseas entities. The Assessing Officer's satisfaction for making the reference was discernible from the recorded shareholding facts; no separate speaking recording of satisfaction was required.
Conclusion: The entities were associated enterprises and the reference for determination of arm's-length price was valid, in favour of the Revenue.
Issue (ii): Whether Chapter X can bring to tax notional income absent an independent charge under sections 4 and 5.
Analysis: Chapter X supplies the machinery for computing the arm's-length value of an international transaction and does not alter either the head or nature of income. Income arising from the technology transactions remained business income chargeable under sections 4 and 5.
Conclusion: Chapter X validly applies as a computation mechanism and does not create an impermissible charge of notional income, in favour of the Revenue.
Issue (iii): Whether an arm's-length-price adjustment made without selecting a prescribed most appropriate method could be sustained.
Analysis: Section 92 requires income from an international transaction to be computed having regard to arm's-length price, while section 92C(1) requires application of a prescribed most appropriate method. The ad hoc determination did not apply such a method. The assessee had also not furnished the prescribed report or its arm's-length-price computation because it denied associated-enterprise status.
Conclusion: The arm's-length-price determination was set aside and remitted for de novo determination under Chapter X; the relief is limited to fresh adjudication, in part in favour of the assessee.
Issue (iv): Whether capital research expenditure qualified for deduction under section 35(1)(iv).
Analysis: Section 35(1)(iv) permits deduction for capital expenditure on scientific research only where the research relates to the business carried on by the assessee. The research expenditure was incurred to develop marketable technology for group concerns and facilitated their business rather than an extension of the assessee's own business.
Conclusion: Deduction under section 35(1)(iv) was not allowable, in favour of the Revenue.
Issue (v): Whether an unpaid provision for leave encashment was deductible.
Analysis: The provision remained unpaid up to the due date for filing the return. Section 43B allows the deduction only upon the prescribed payment condition being satisfied.
Conclusion: The disallowance of the unpaid leave-encashment provision was sustained, in favour of the Revenue.
Issue (vi): Whether software expenditure was capital or revenue according to the duration of its benefit.
Analysis: Software intended for use over an indeterminate or extended period confers an enduring benefit and remains capital notwithstanding that it replaces or upgrades existing software. Conversely, software having validity limited to one year does not confer an enduring benefit extending beyond that period.
Conclusion: Expenditure on long-term software was capital and its disallowance was sustained in favour of the Revenue; expenditure on one-year software was revenue and allowable in favour of the assessee.
Issue (vii): Whether expenditure on a handy camera was allowable business or research expenditure rather than impermissible freebies.
Analysis: The stated use of the handy camera for recording clinical trials and research activities was not accepted. The expenditure was treated as a prohibited freebie rather than expenditure incurred for the assessee's business or research.
Conclusion: The disallowance of the handy-camera expenditure was sustained, in favour of the Revenue.
Issue (viii): Whether research and development expenditure claimed as revenue expenditure under section 37 was capital expenditure.
Analysis: The character of research expenditure depends on its intended long-term benefit, not on whether the research ultimately results in a successful product or technology. Research undertaken to obtain enduring benefit is capital in nature. As the necessary bifurcation and supporting details were unavailable, the claim required fresh factual adjudication.
Conclusion: The deletion of the research-and-development disallowance was set aside and the issue was remitted for de novo adjudication, in favour of the Revenue to that extent.
Final Conclusion: Associated-enterprise status and the statutory conditions governing scientific-research, leave-encashment, software and research expenditure claims were upheld as applied; arm's-length-price and research-expenditure computations requiring proper factual and statutory determination must be reconsidered afresh.
Ratio Decidendi: Where the statutory deeming conditions in section 92A(2) are met, associated-enterprise status follows, and any arm's-length-price adjustment must be determined through a prescribed method under section 92C.